# Changelog — v1.8.2

## v1.8.2 — October 20, 2026

Metadata only: title, tags, description and one added finding changed; zero data cells changed.
primary_changed_cells: 0

1. README.md: H1 and YAML pretty_name now use the requested full title; YAML tags are the exact 17 requested tags. October 2026 remains the snapshot label, not part of the title.
2. README.md: the opening answers the post-intake pricing question and names Pretty Girls Peptide as publisher; the summary adds one sentence for each of the eight requested categories. Ranges are computed from medication_cost_monthly_usd in the 96 observed rows of combined_pricing.csv, joined to quote-detail categories through primary_csv_row. PGP configured offers are not described as observed quotes. Four native-week plans remain unconverted and are excluded from monthly ranges. Unknown required fees remain unknown. The existing evidence-class and collection_basis explanation is preserved verbatim. Counts remain 128 combined, 96 observed and 32 configured PGP rows.
3. findings.json and the README dated findings list: added F09, sourced only to ageless-pt141-monthly-post-questionnaire-20261019. The selected one-month-labelled PT-141 injection total is $149 after PT141INJ50, conditional on prescription, with $199 monthly renewal and $0 displayed due now. All F01–F08 objects and source-record dates are unchanged.
4. README active version/citation, CITATION.cff title/version, RELEASE.json version/release_tag/previous_release, and active metadata version markers are updated to 1.8.2. The release date remains 2026-10-20. Previous release is 1.8.0; no 1.8.1 release existed on the verified mirrors. Historical release entries remain unchanged.
5. RELEASE-QUALITY.json now records this metadata-only validation, with nine findings. SHA256SUMS.txt is regenerated for the same 483-file payload.
6. Platform metadata: GitHub description and topics use the requested title and topic list; the v1.8.2 Release carries the same files as Hugging Face. Kaggle uses the publisher-approved short title “GLP-1 & Peptide Pricing After the Intake Quiz” because its title field permits 50 characters, while the full requested title remains in its description and unchanged canonical README. Kaggle receives the same v1.8.2 files and summary, plus F09. Platform tags are applied where supported, with any restrictions recorded outside this immutable payload.

No CSV, JSONL, Parquet, price, term, collection date, source URL, observation ID, collection_basis label or evidence file changed. Repository and dataset slugs are unchanged. CC BY 4.0 and the third-party evidence exception remain unchanged. DOI remains on hold.

## v1.8.0 — October 20, 2026

Default-view and price-findings release. Previous release v1.7.3 is preserved. `primary_changed_cells: 0`; no observed price, plan term, collection date, source URL or observation ID changed.

### Every release change

1. README.md YAML: default now points to combined_pricing.csv (128 rows, 16 columns), with default: true. Added observed_quotes_only pointing to pricing.csv (96 rows, 15 columns). The five other configs retain their data files; combined_all_providers remains the explicit combined-table alias and primary_parquet remains CSV-backed.
2. README.md summary and loading instructions: identify the combined table as the default, document loading with no config argument and the observed-only selection, preserve the two-evidence-class warning, and distinguish direct file downloads. Updated the main-file description, schema explanations and current combined-view references.
3. README.md dated findings and findings.json: preserved F01 exactly; replaced F02–F05 and F08 and updated F07 with source-backed price facts; retained F06’s price sentence. The eight findings now contain seven concrete price facts, including three PGP facts and no additional methodology statistic. Added structured provider/product/term/total, renewal status, collection basis, source URL and original record date to price facts. The dated fact list is below.
4. README.md Comparison highlights: added four PGP benchmark rows (listed below), each marked publisher-configured with renewal not independently observed. Updated table headings and the explanatory paragraph to cover observed and configured totals without implying equivalent supply or an observed checkout.
5. CITATION.cff: version is 1.8.0; date-released remains 2026-10-20. README.md and METHODS.md active citations point to v1.8.0; historical release labels remain unchanged.
6. RELEASE.json: version/release_tag/previous_release become 1.8.0/v1.8.0/1.7.3; config mapping matches YAML; added default config/file/row/column/provider fields and observed_quotes_config; updated the combined-view scope. Current primary_changed_cells and primary_row_changes_from_source are 0; inherited v1.7.2 counts are no longer reported as current-release changes. Data-file hashes are unchanged.
7. research-status.json: active version and previous release updated; current primary_metadata_cells_changed is 0; added default config/file/row count and observed-only config. All source collection dates and coverage records remain unchanged.
8. schema.json: active release version updated; added default_view and observed_quotes_only declarations. Existing observed columns and combined evidence-class definitions are unchanged.
9. METHODS.md: replaced stale unpublished status, distinguished the observed-only inclusion rule from the combined default, updated the current QA version and citation, and documented v1.8.0 findings and benchmark-total handling.
10. RELEASE-QUALITY.json: replaced the previous-release audit report with v1.8.0 validation results, including the seven official-loader configs and default loading without a config argument. SHA256SUMS.txt regenerated.

### Dated findings (source records remain dated as originally collected)

| ID | Finding | Source observation ID |
|---|---|---|
|F02|Pretty Girls Peptide’s publisher-configured Semaglutide Plan (injection) records a $175 total for the one-month billing interval; checkout renewal was not independently observed.|`B-pgp-config-plan3357-variant20308-20261019`|
|F03|Pretty Girls Peptide’s publisher-configured Tirzepatide Plan (injection) records a $597 total for the quarterly (three-month) billing interval; checkout renewal was not independently observed.|`B-pgp-config-plan3372-variant20335-20261019`|
|F04|Pretty Girls Peptide’s publisher-configured NAD+ Nasal Spray 300 mg/mL plan records a $525 total for the quarterly (three-month) billing interval; checkout renewal was not independently observed.|`B-pgp-config-plan3804-variant22314-20261019`|
|F05|Good Life Meds’ selected one-month-labelled NAD+ nasal spray quote showed a $111.20 total after DW20, compared with $139 before the code; the promotion’s renewal amount was not established.|`goodlife-nad-nasal-monthly-new-research-20261019`|
|F06|AgelessRx’s selected monthly compounded tirzepatide quote showed $279 initially with the displayed CTG70 promotion and $349 on monthly renewal.|`ageless-compounded-tirzepatide-monthly-post-questionnaire-20261019`|
|F07|Lovely Meds’ selected three-month-labelled tirzepatide injection plan showed a $537 initial total after NEW60, compared with $597 before the code; an exact future renewal total was not itemized.|`lovely-tirzepatide-injection-3m-research-20261020`|
|F08|AgelessRx’s selected four-month-labelled Personalized Compounded Semaglutide + Glycine injection plan showed an $856 initial total after TSEMA100 and $956 on four-month renewal.|`ageless-compounded-semaglutide-4m-post-questionnaire-20261020`|

### PGP comparison additions

| Benchmark observation ID | Product | Configured billing interval | Configured total |
|---|---|---|---:|
|`B-pgp-config-plan3357-variant20308-20261019`|Semaglutide Plan|1 month(s)|$175.00|
|`B-pgp-config-plan3372-variant20334-20261019`|Tirzepatide Plan|1 month(s)|$225.00|
|`B-pgp-config-plan3372-variant20335-20261019`|Tirzepatide Plan|3 month(s)|$597.00|
|`B-pgp-config-plan3804-variant22314-20261019`|NAD+ Nasal Spray 300mg/mL|3 month(s)|$525.00|

### Verification

- pricing.csv: 96 rows; publisher benchmark: 32 rows; combined_pricing.csv: 128 rows. Both Parquet tables are byte-for-byte unchanged.
- Every CSV, JSONL, evidence and support-evidence file is byte-for-byte unchanged from v1.7.3. No data row was rewritten.
- All 128 collection_basis values remain exactly as before: 96 post_questionnaire_selected_quote and 32 owner_verified_configured_benchmark.
- All seven configs passed the official datasets loader locally. Omitting the config selects the 128-row default.
- Every displayed price fact and PGP comparison addition reconciles to its original source row; unknown renewal totals remain unknown.
- CC BY 4.0, third-party evidence rights and DOI hold remain unchanged.


## v1.7.3 — October 20, 2026

Typography only — no data, price, term, or wording changes; `primary_changed_cells: 0`.

All CSV, JSONL, benchmark, combined-table, Parquet and screenshot bytes are unchanged from v1.7.2. Counts remain pricing 96, benchmark 32 and combined 128. Active version references and checksums are updated. v1.7.2 remains preserved.

### Every spacing correction

Line numbers below refer to v1.7.2. Original spellings are retained only as inline-code audit examples. Legitimate promotion codes, observation IDs, source IDs, URLs, YAML tokens and historical version numbers are preserved.

| File | v1.7.2 line | Before | After |
|---|---:|---|---|
|CHANGELOG.md|124|`Added18`|`Added 18`|
|CHANGELOG.md|124|`October20,2026`|`October 20, 2026`|
|CHANGELOG.md|124|`nasal15mL300mg/mL`|`nasal 15 mL 300 mg/mL`|
|CHANGELOG.md|124|`with1/3/6/12`|`with 1/3/6/12`|
|README.md|153|`30ml`|`30 ml`|
|README.md|154|`200mg/ml`|`200 mg/ml`|
|README.md|158|`30ml`|`30 ml`|
|README.md|166|`All78 prior quotes`|`All 78 prior quotes`|
|README.md|166|`contains96 primary options,480 scoped metadata reviews and99 public comparison records`|`contains 96 primary options, 480 scoped metadata reviews and 99 public comparison records`|
|README.md|166|`for1/3-month-labelled`|`for 1/3-month-labelled`|
|README.md|168|`All74 preceding quote economics`|`All 74 preceding quote economics`|
|README.md|168|`All78 primary options`|`All 78 primary options`|
|README.md|168|`a49-state background claim`|`a 49-state background claim`|
|README.md|168|`added20 previously missing comparisons`|`added 20 previously missing comparisons`|
|README.md|168|`all78 current selected totals`|`all 78 current selected totals`|
|README.md|168|`reviewed390 requested metadata cells`|`reviewed 390 requested metadata cells`|

### v1.7.3 verification

- Prose changes insert spaces only; no existing non-whitespace wording changed.
- Letter-digit and digit-letter pattern searches found no remaining unintended prose fusions.
- Pricing CSV: 96 rows; publisher benchmark: 32 rows; combined CSV: 128 rows.
- Every CSV, JSONL and Parquet file is byte-for-byte identical to v1.7.2.
- Both Parquet tables retain the same contents and row counts.
- The dataset-card YAML, six configurations, licensing and citation release date are unchanged.
- SHA256SUMS.txt is regenerated; DOI generation remains on hold.

## v1.7.2

Date: October 20, 2026. Previous release v1.7.1 is preserved. This release changes 106 cells in pricing.csv and its equivalent primary encodings; no observed economic value changed. CSV row numbers include the header.

The combined view adds 32 PGP benchmark mappings and one collection_basis column; it does not turn the benchmark into post-questionnaire observations. PGP monthly bundle rates are configured period charge / billing interval months. Membership allocation, states and pharmacy names remain unverified. Source references remain byte-for-byte the benchmark references.

## Every changed primary cell

| CSV row | Observation ID | Field | Before | After | Source ID |
|---:|---|---|---|---|---|
|2|ageless-ghk-cream-05-monthly-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|3|ageless-gsh-injection-1m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|4|ageless-gsh-injection-3m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|5|ageless-nad-nasal-monthly-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|6|ageless-pt141-monthly-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|7|ageless-compounded-semaglutide-1m-post-questionnaire-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|8|ageless-compounded-semaglutide-2m-post-questionnaire-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|9|ageless-compounded-semaglutide-4m-post-questionnaire-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|10|ageless-compounded-tirzepatide-monthly-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|11|ageless-tirz-micro-trial-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-agelessrx.com|
|12|amble-glutathione-new-research-1m-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-joinamble.com|
|13|amble-glutathione-new-research-3m-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-joinamble.com|
|14|amble-glutathione-new-research-6m-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-joinamble.com|
|15|amble-semaglutide-new-research-1m-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-joinamble.com|
|16|amble-semaglutide-new-research-3m-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-joinamble.com|
|17|amble-semaglutide-new-research-6m-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-joinamble.com|
|18|amble-tirzepatide-new-research-1m-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-joinamble.com|
|19|amble-tirzepatide-new-research-3m-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-joinamble.com|
|20|amble-tirzepatide-new-research-6m-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-joinamble.com|
|21|arbor-glutathione-resumed-1m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|22|arbor-glutathione-resumed-3m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|23|arbor-glutathione-resumed-6m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|24|arbor-glutathione-resumed-12m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|25|arbor-semaglutide-1-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|26|arbor-semaglutide-3-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|27|arbor-semaglutide-6-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|28|arbor-semaglutide-12-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|29|arbor-tirzepatide-injection-1-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|30|arbor-tirzepatide-3-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|31|arbor-tirzepatide-6-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|32|arbor-tirzepatide-12-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-startarbor.com|
|33|effecty-glutathione-1m-fresh-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|34|effecty-glutathione-3m-fresh-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|35|effecty-glutathione-6m-fresh-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|36|effecty-glutathione-12m-fresh-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|37|effecty-round2-semaglutide-1m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|38|effecty-round2-semaglutide-3m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|39|effecty-round2-semaglutide-6m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|40|effecty-round2-semaglutide-12m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|41|effecty-round2-tirzepatide-1m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|42|effecty-round2-tirzepatide-3m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|43|effecty-round2-tirzepatide-6m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|44|effecty-round2-tirzepatide-12m-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-effecty.com|
|45|Q-fitish-wellness-ghk-1m|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|46|Q-fitish-wellness-ghk-3m|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|47|Q-fitish-wellness-ghk-6m|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|48|Q-fitish-wellness-nad-1m|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|49|Q-fitish-wellness-nad-3m|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|50|Q-fitish-wellness-nad-6m|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|51|Q-fitish-followup-004|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|52|Q-fitish-followup-005|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|53|Q-fitish-followup-006|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|54|Q-fitish-followup-001|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|55|Q-fitish-followup-002|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|56|Q-fitish-followup-003|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|57|Q-fitish-microdose-followup-001|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|58|Q-fitish-microdose-followup-002|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|59|Q-fitish-microdose-followup-003|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-fitish.com|
|60|goodlife-glutathione-monthly-new-research-20261019|pharmacy_named_publicly|Not established in reviewed sources|Yes (GoGo Meds d/b/a Jungle Jims; Pharmacy Hub — named in the provider's Terms as its fulfillment pharmacies; assignment to an individual prescription unverified).|V172-GOODLIFE-TERMS-PHARMACY|
|60|goodlife-glutathione-monthly-new-research-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-goodlifemeds.com|
|61|goodlife-glutathione-one-time-new-research-20261019|pharmacy_named_publicly|Not established in reviewed sources|Yes (GoGo Meds d/b/a Jungle Jims; Pharmacy Hub — named in the provider's Terms as its fulfillment pharmacies; assignment to an individual prescription unverified).|V172-GOODLIFE-TERMS-PHARMACY|
|61|goodlife-glutathione-one-time-new-research-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-goodlifemeds.com|
|62|goodlife-glutathione-quarterly-new-research-20261019|pharmacy_named_publicly|Not established in reviewed sources|Yes (GoGo Meds d/b/a Jungle Jims; Pharmacy Hub — named in the provider's Terms as its fulfillment pharmacies; assignment to an individual prescription unverified).|V172-GOODLIFE-TERMS-PHARMACY|
|62|goodlife-glutathione-quarterly-new-research-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-goodlifemeds.com|
|63|goodlife-nad-nasal-monthly-new-research-20261019|pharmacy_named_publicly|Not established in reviewed sources|Yes (GoGo Meds d/b/a Jungle Jims; Pharmacy Hub — named in the provider's Terms as its fulfillment pharmacies; assignment to an individual prescription unverified).|V172-GOODLIFE-TERMS-PHARMACY|
|63|goodlife-nad-nasal-monthly-new-research-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-goodlifemeds.com|
|64|goodlife-tirzepatide-new-research-4w-20261019|pharmacy_named_publicly|Not established in reviewed sources|Yes (GoGo Meds d/b/a Jungle Jims; Pharmacy Hub — named in the provider's Terms as its fulfillment pharmacies; assignment to an individual prescription unverified).|V172-GOODLIFE-TERMS-PHARMACY|
|64|goodlife-tirzepatide-new-research-4w-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-goodlifemeds.com|
|65|goodlife-tirzepatide-new-research-8w-20261019|pharmacy_named_publicly|Not established in reviewed sources|Yes (GoGo Meds d/b/a Jungle Jims; Pharmacy Hub — named in the provider's Terms as its fulfillment pharmacies; assignment to an individual prescription unverified).|V172-GOODLIFE-TERMS-PHARMACY|
|65|goodlife-tirzepatide-new-research-8w-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-goodlifemeds.com|
|66|goodlife-tirzepatide-microdose-4w-new-research-20261019|pharmacy_named_publicly|Not established in reviewed sources|Yes (GoGo Meds d/b/a Jungle Jims; Pharmacy Hub — named in the provider's Terms as its fulfillment pharmacies; assignment to an individual prescription unverified).|V172-GOODLIFE-TERMS-PHARMACY|
|66|goodlife-tirzepatide-microdose-4w-new-research-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-goodlifemeds.com|
|67|goodlife-tirzepatide-microdose-12w-new-research-20261019|pharmacy_named_publicly|Not established in reviewed sources|Yes (GoGo Meds d/b/a Jungle Jims; Pharmacy Hub — named in the provider's Terms as its fulfillment pharmacies; assignment to an individual prescription unverified).|V172-GOODLIFE-TERMS-PHARMACY|
|67|goodlife-tirzepatide-microdose-12w-new-research-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-goodlifemeds.com|
|68|lovely-glutathione-injection-1m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|69|lovely-glutathione-injection-3m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|70|lovely-glutathione-injection-6m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|71|lovely-glutathione-injection-12m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|72|lovely-nad-nasal-15ml-1m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|73|lovely-nad-nasal-15ml-3m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|74|lovely-nad-nasal-15ml-6m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|75|lovely-nad-nasal-15ml-12m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|76|lovely-semaglutide-injection-1m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|77|lovely-semaglutide-injection-3m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|78|lovely-semaglutide-injection-6m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|79|lovely-semaglutide-injection-12m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|80|lovely-tirzepatide-injection-1m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|81|lovely-tirzepatide-injection-3m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|82|lovely-tirzepatide-injection-6m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|83|lovely-tirzepatide-injection-12m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|84|lovely-tirzepatide-sublingual-drops-1m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|85|lovely-tirzepatide-sublingual-drops-3m-research-20261020|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-lovelymeds.com|
|86|readyrx-glutathione-injection-1-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|87|readyrx-glutathione-nasal-1-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|88|readyrx-glutathione-injection-3-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|89|readyrx-glutathione-nasal-3-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|90|readyrx-nad-nasal-1-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|90|readyrx-nad-nasal-1-month-post-questionnaire-20261019|fda_approved_medication|Not verified|No|V172-READYRX-NAD-NASAL-FAQ|
|91|readyrx-nad-nasal-3-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|91|readyrx-nad-nasal-3-month-post-questionnaire-20261019|fda_approved_medication|Not verified|No|V172-READYRX-NAD-NASAL-FAQ|
|92|readyrx-semaglutide-1-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|93|readyrx-semaglutide-3-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|94|readyrx-semaglutide-6-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|95|readyrx-tirzepatide-1-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|96|readyrx-tirzepatide-3-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|
|97|readyrx-tirzepatide-6-month-post-questionnaire-20261019|legitscript_certified|Not independently verified|Yes|V172-LEGITSCRIPT-readyrx.com|

## Other release changes

- Added combined_pricing.csv (128 rows, 16 columns), combined_pricing.parquet and combined_all_providers config. Regenerated pricing.parquet (96 rows, 15 columns).
- Updated current metadata and source provenance, including publisher-confirmed LegitScript reads and the Good Life Meds state-claim conflict. Sources are dated 2026-10-20.
- Preserved PGP benchmark source files and all original screenshot evidence unchanged.
- Updated README findings context, certification section, active version references, CITATION.cff, schema, release status and checksums. Historical changelog entries retain their original version labels.
- Corrected Added 18, nasal 15 mL 300 mg/mL, with 1/3/6/12 and October 20, 2026 spacing in the card.
- CC BY 4.0 continues to cover PGP original data and writing; third-party evidence retains its rights exception. DOI generation remains on hold.

- Release-candidate loader correction: retained primary_parquet as a CSV-backed alias so all six named configurations load with the shared CSV builder. Actual pricing.parquet and combined_pricing.parquet are retained as independently verified alternate encodings. No table cell changed in this loader correction.